title: Esthesioneuroblastoma.
abstract: Esthesioneuroblastoma is a rare tumor for which the published literature does not provide an evidence-based consensus treatment approach. Multimodality therapy including a combination of surgery and radiation appears to provide the best disease-free and overall survival. Surgical resection should proceed through a craniofacial approach if possible. The role of chemotherapy in the initial treatment paradigm is less clear. Chemotherapy should not be used as single-modality therapy for initial treatment but may provide additional benefit when used in combination with radiation and surgery, particularly in advanced-stage disease. Combination chemotherapy should be considered as initial therapy for unresectable tumors and metastatic disease, and as salvage therapy in disease recurrence.
authors.affiliation: Section of Hematology and Oncology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. hklepin@wfubmc.edu
authors.forename: Heidi D
authors.initials: HD
authors.lastname: Klepin
authors.forename: Kevin P
authors.initials: KP
authors.lastname: McMullen
authors.forename: Glenn J
authors.initials: GJ
authors.lastname: Lesser
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018304:Esthesioneuroblastoma, Olfactory / Q000628:therapy*; D006801:Humans; D009296:Nasal Cavity / Q000473:pathology*; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000628:therapy*